Literature DB >> 33148005

Traditional Chinese Medicine Formulation Therapy in the Treatment of Coronavirus Disease 2019 (COVID-19).

Jia Shi1, Yunfei Lu1, Yuan Zhang1, Lu Xia2, Chen Ye1, Ying Lü1, Shishi Chen1, Qingnian Xu1, Bozong Tang1, Keshan Yin1, Jing Zhang1, Xiaorong Chen1, Zongguo Yang1.   

Abstract

This study aimed to investigate the efficacy of Traditional Chinese Medicine (TCM) decoction with different intervention timepoints in the treatment of coronavirus disease 2019 (COVID-19) patients. We retrospectively collected the medical records and evaluated the outcomes of COVID-19 patients that received TCM decoction treatment at different timepoints. A total of 234 COVID-19 patients were included in this study. Patients who received TCM decoction therapy within 3 days or 7 days after admission could achieve shorter hospitalization days and disease periods compared to those who received TCM decoction [Formula: see text] 7 days after admission (all [Formula: see text]). Patients who received TCM decoction therapy within 3 days had significantly fewer days to negative SARS-CoV-2 from nasopharyngeal/oral swab and days to negative SARS-CoV-2 from urine/stool/blood samples compared to those received TCM decoction [Formula: see text] days after admission (all [Formula: see text]). Patients who received TCM decoction therapy on the 3rd to 7th day after admission had a faster achievement of negative SARS-CoV-2 from urine/stool/blood samples compared to those who received TCM decoction [Formula: see text] days after admission ([Formula: see text]). Logistic models revealed that more days from TCM decoction to admission [Formula: see text] days might be a risk factor for long hospitalization days, disease period, and slower negative-conversion of SARS-CoV-2 (all [Formula: see text]). Conclusively, our results suggest that TCM decoction therapy should be considered at the early stage of COVID-19 patients.

Entities:  

Keywords:  COVID-19; Clinical Study; Coronavirus; Decoction; Formulation; Herbs; SARS-CoV-2; Traditional Chinese Medicine

Mesh:

Substances:

Year:  2020        PMID: 33148005     DOI: 10.1142/S0192415X20500755

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  3 in total

1.  Effectiveness and Safety of Traditional Chinese Medicine in Treating COVID-19: Clinical Evidence from China.

Authors:  Dongmei Xing; Zhibin Liu
Journal:  Aging Dis       Date:  2021-12-01       Impact factor: 6.745

2.  Effects of Modified Jianpi Qushi Heluo Decoction on Scores of TCM Syndromes, 24 h Urinary Albumin, and Plasma Albumin in IMN of Spleen-Kidney Qi Deficiency.

Authors:  KaiPi Wu; HongAi Yin; AnMin Du
Journal:  Emerg Med Int       Date:  2022-07-11       Impact factor: 1.621

3.  Exploration of molecular targets and mechanisms of Chinese medicinal formula Acacia Catechu -Scutellariae Radix in the treatment of COVID-19 by a systems pharmacology strategy.

Authors:  Tian Feng; Meng Zhang; Qiong Xu; Fan Song; Libin Wang; Shouchang Gai; Haifeng Tang; Siwang Wang; Liying Zhou; Hua Li
Journal:  Phytother Res       Date:  2022-07-20       Impact factor: 6.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.